181 related articles for article (PubMed ID: 28455974)
1. Strategies for HCC target discovery.
Molina-Sánchez P; Lujambio A
Aging (Albany NY); 2017 Apr; 9(4):1088-1089. PubMed ID: 28455974
[No Abstract] [Full Text] [Related]
2. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
[TBL] [Abstract][Full Text] [Related]
4. Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator.
Nault JC
Gastroenterology; 2017 Apr; 152(5):941-943. PubMed ID: 28259794
[No Abstract] [Full Text] [Related]
5. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma.
Nie JJ; Liu Y; Qi Y; Zhang N; Yu B; Chen DF; Yang M; Xu FJ
J Control Release; 2021 May; 333():362-373. PubMed ID: 33785418
[TBL] [Abstract][Full Text] [Related]
6. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9.
Kieckhaefer JE; Maina F; Wells RG; Wangensteen KJ
Semin Liver Dis; 2019 May; 39(2):261-274. PubMed ID: 30912094
[TBL] [Abstract][Full Text] [Related]
7. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
8. Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes.
Morgens DW; Deans RM; Li A; Bassik MC
Nat Biotechnol; 2016 Jun; 34(6):634-6. PubMed ID: 27159373
[TBL] [Abstract][Full Text] [Related]
9. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.
Evers B; Jastrzebski K; Heijmans JP; Grernrum W; Beijersbergen RL; Bernards R
Nat Biotechnol; 2016 Jun; 34(6):631-3. PubMed ID: 27111720
[TBL] [Abstract][Full Text] [Related]
10. Personalized therapy for hepatocellular carcinoma: Where are we now?
Chan SL; Wong AM; Lee K; Wong N; Chan AK
Cancer Treat Rev; 2016 Apr; 45():77-86. PubMed ID: 26995632
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform.
Wangensteen KJ; Wang YJ; Dou Z; Wang AW; Mosleh-Shirazi E; Horlbeck MA; Gilbert LA; Weissman JS; Berger SL; Kaestner KH
Hepatology; 2018 Aug; 68(2):663-676. PubMed ID: 29091290
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia.
Liu Q; Garcia M; Wang S; Chen CW
Cells; 2020 Aug; 9(8):. PubMed ID: 32806592
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
14. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
Pan J; Zhang M; Dong L; Ji S; Zhang J; Zhang S; Lin Y; Wang X; Ding Z; Qiu S; Gao D; Zhou J; Fan J; Gao Q
Autophagy; 2023 Apr; 19(4):1184-1198. PubMed ID: 36037300
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
16. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.
Chen B; Garmire L; Calvisi DF; Chua MS; Kelley RK; Chen X
Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):238-251. PubMed ID: 31900465
[TBL] [Abstract][Full Text] [Related]
17. Current discovery strategies for hepatocellular carcinoma therapeutics.
Dai Q; Zhang C; Yuan Z; Sun Q; Jiang Y
Expert Opin Drug Discov; 2020 Feb; 15(2):243-258. PubMed ID: 31809618
[No Abstract] [Full Text] [Related]
18. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
19. Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles.
Boilève A; Smolenschi C; Fuerea A; Hollebecque A; Boige V
Dig Liver Dis; 2021 Aug; 53(8):1059-1061. PubMed ID: 34030987
[No Abstract] [Full Text] [Related]
20. Refametinib in RAS-mutated hepatocellular cancer.
Das M
Lancet Oncol; 2018 Aug; 19(8):e389. PubMed ID: 29983345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
